Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity

Cancer Cell

Volumn 23, Issue 4, 2013, Pages 516-526

  Engels, Boris ^a   Engelhard, Victor H ^b   Sidney, John ^c   Sette, Alessandro ^c   Binder, David C ^a   Liu, Rebecca B ^a   Kranz, David M ^d   Meredith, Stephen C ^a   Rowley, Donald A ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; T LYMPHOCYTE;

EID: 84876381248     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.03.018     Document Type: Article

References (60)

1. Anders K., Buschow C., Herrmann A., Milojkovic A., Loddenkemper C., Kammertoens T., Daniel P., Yu H., Charo J., Blankenstein T. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 2011, 20:755-767.
2. Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., Klebanoff C.A., Overwijk W.W., et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174:2591-2601.
3. Assarsson E., Sidney J., Oseroff C., Pasquetto V., Bui H.H., Frahm N., Brander C., Peters B., Grey H., Sette A. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J. Immunol. 2007, 178:7890-7901.
4. Bowerman N.A., Colf L.A., Garcia K.C., Kranz D.M. Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides. J. Biol. Chem. 2009, 284:32551-32561.
5. Budhu S., Loike J.D., Pandolfi A., Han S., Catalano G., Constantinescu A., Clynes R., Silverstein S.C. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J. Exp. Med. 2010, 207:223-235.
6. Buschow C., Charo J., Anders K., Loddenkemper C., Jukica A., Alsamah W., Perez C., Willimsky G., Blankenstein T. In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance. J. Immunol. 2010, 184:2930-2938.
7. Chapiro J., Claverol S., Piette F., Ma W., Stroobant V., Guillaume B., Gairin J.E., Morel S., Burlet-Schiltz O., Monsarrat B., et al. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 2006, 176:1053-1061.
8. Cheever M.A., Greenberg P.D., Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 1980, 125:711-714.
9. Cho H.I., Reyes-Vargas E., Delgado J.C., Celis E. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res. 2012, 72:1986-1995.
10. Colella T.A., Bullock T.N., Russell L.B., Mullins D.W., Overwijk W.W., Luckey C.J., Pierce R.A., Restifo N.P., Engelhard V.H. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 2000, 191:1221-1232.
11. Corr M., Slanetz A.E., Boyd L.F., Jelonek M.T., Khilko S., al-Ramadi B.K., Kim Y.S., Maher S.E., Bothwell A.L., Margulies D.H. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science 1994, 265:946-949.
12. Davis M.M., Boniface J.J., Reich Z., Lyons D., Hampl J., Arden B., Chien Y. Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol. 1998, 16:523-544.
13. Dubey P., Hendrickson R.C., Meredith S.C., Siegel C.T., Shabanowitz J., Skipper J.C., Engelhard V.H., Hunt D.F., Schreiber H. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med. 1997, 185:695-705.
14. Dummer W., Niethammer A.G., Baccala R., Lawson B.R., Wagner N., Reisfeld R.A., Theofilopoulos A.N. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 2002, 110:185-192.
15. Fujita T., Nolan G.P., Ghosh S., Baltimore D. Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B. Genes Dev. 1992, 6:775-787.
16. Garcia K.C., Tallquist M.D., Pease L.R., Brunmark A., Scott C.A., Degano M., Stura E.A., Peterson P.A., Wilson I.A., Teyton L. Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. Proc. Natl. Acad. Sci. USA 1997, 94:13838-13843.
17. Garcia-Hernandez Mde.L., Hamada H., Reome J.B., Misra S.K., Tighe M.P., Dutton R.W. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J. Immunol. 2010, 184:4215-4227.
18. Gattinoni L., Finkelstein S.E., Klebanoff C.A., Antony P.A., Palmer D.C., Spiess P.J., Hwang L.N., Yu Z., Wrzesinski C., Heimann D.M., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
19. Gattinoni L., Zhong X.S., Palmer D.C., Ji Y., Hinrichs C.S., Yu Z., Wrzesinski C., Boni A., Cassard L., Garvin L.M., et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 2009, 15:808-813.
20. Gold J.S., Ferrone C.R., Guevara-Patiño J.A., Hawkins W.G., Dyall R., Engelhorn M.E., Wolchok J.D., Lewis J.J., Houghton A.N. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J. Immunol. 2003, 170:5188-5194.
21. Gottschalk R.A., Hathorn M.M., Beuneu H., Corse E., Dustin M.L., Altan-Bonnet G., Allison J.P. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc. Natl. Acad. Sci. USA 2012, 109:881-886.
22. Gregg R.K., Nichols L., Chen Y., Lu B., Engelhard V.H. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J. Immunol. 2010, 184:1909-1917.
23. Hanson H.L., Donermeyer D.L., Ikeda H., White J.M., Shankaran V., Old L.J., Shiku H., Schreiber R.D., Allen P.M. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000, 13:265-276.
24. Hensley S.E., Das S.R., Bailey A.L., Schmidt L.M., Hickman H.D., Jayaraman A., Viswanathan K., Raman R., Sasisekharan R., Bennink J.R., Yewdell J.W. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009, 326:734-736.
25. Ho W.Y., Blattman J.N., Dossett M.L., Yee C., Greenberg P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003, 3:431-437.
26. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
27. Holler P.D., Kranz D.M. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003, 18:255-264.
28. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., Robbins P.F., Sette A., Appella E., Rosenberg S.A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 1995, 154:3961-3968.
29. Li Y., Karlin A., Loike J.D., Silverstein S.C. A critical concentration of neutrophils is required for effective bacterial killing in suspension. Proc. Natl. Acad. Sci. USA 2002, 99:8289-8294.
30. Li Y., Karlin A., Loike J.D., Silverstein S.C. Determination of the critical concentration of neutrophils required to block bacterial growth in tissues. J. Exp. Med. 2004, 200:613-622.
31. Listopad J.J., Kammertoens T., Anders K., Silkenstedt B., Willimsky G., Schmidt K., Kuehl A.A., Loddenkemper C., Blankenstein T. Fas expression by tumor stroma is required for cancer eradication. Proc. Natl. Acad. Sci. USA 2013, 110:2276-2281.
32. Ly L.V., Sluijter M., Versluis M., Luyten G.P., van Stipdonk M.J., van der Burg S.H., Melief C.J., Jager M.J., van Hall T. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res. 2010, 70:8339-8346.
33. Matsui K., O'Mara L.A., Allen P.M. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int. Immunol. 2003, 15:797-805.
34. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
35. Moutaftsi M., Salek-Ardakani S., Croft M., Peters B., Sidney J., Grey H., Sette A. Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur. J. Immunol. 2009, 39:717-722.
36. Newberg M.H., Smith D.H., Haertel S.B., Vining D.R., Lacy E., Engelhard V.H. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 1996, 156:2473-2480.
37. Nichols L.A., Chen Y., Colella T.A., Bennett C.L., Clausen B.E., Engelhard V.H. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J. Immunol. 2007, 179:993-1003.
38. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982, 155:1063-1074.
39. Overwijk W.W., Tsung A., Irvine K.R., Parkhurst M.R., Goletz T.J., Tsung K., Carroll M.W., Liu C., Moss B., Rosenberg S.A., Restifo N.P. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self" -reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 1998, 188:277-286.
40. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., Dellemijn T.A., Antony P.A., Spiess P.J., Palmer D.C., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 2003, 198:569-580.
41. Palmer D.C., Chan C.C., Gattinoni L., Wrzesinski C., Paulos C.M., Hinrichs C.S., Powell D.J., Klebanoff C.A., Finkelstein S.E., Fariss R.N., et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl. Acad. Sci. USA 2008, 105:8061-8066.
42. *0201-binding residues. J. Immunol. 1996, 157:2539-2548.
43. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., Davis J.L., Morgan R.A., Merino M.J., Sherry R.M., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19:620-626.
44. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., Pérarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 1997, 185:2043-2051.
45. Popovic J., Li L.P., Kloetzel P.M., Leisegang M., Uckert W., Blankenstein T. The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 2011, 118:946-954.
46. Purbhoo M.A., Irvine D.J., Huppa J.B., Davis M.M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 2004, 5:524-530.
47. Schreiber K., Wu T.H., Kast W.M., Schreiber H. Tracking the common ancestry of antigenically distinct cancer variants. Clin. Cancer Res. 2001, 7(3, Suppl):871s-875s.
48. Schultz E.S., Chapiro J., Lurquin C., Claverol S., Burlet-Schiltz O., Warnier G., Russo V., Morel S., Lévy F., Boon T., et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. 2002, 195:391-399.
49. Sidney J., Southwood S., Oseroff C., del Guercio M.F., Sette A., Grey H.M. Measurement of MHC/peptide interactions by gel filtration. Curr. Protoc. Immunol. 2001, 31. 18.3.1-18.3.19.
50. Singh S., Ross S.R., Acena M., Rowley D.A., Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 1992, 175:139-146.
51. Skipper H.E. On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future). Bull. Math. Biol. 1986, 48:253-278.
52. Spiotto M.T., Yu P., Rowley D.A., Nishimura M.I., Meredith S.C., Gajewski T.F., Fu Y.X., Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002, 17:737-747.
53. Spiotto M.T., Rowley D.A., Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 2004, 10:294-298.
54. Tsai V., Southwood S., Sidney J., Sakaguchi K., Kawakami Y., Appella E., Sette A., Celis E. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 1997, 158:1796-1802.
55. van Stipdonk M.J., Badia-Martinez D., Sluijter M., Offringa R., van Hall T., Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res. 2009, 69:7784-7792.
56. Wang R., Rogers A.M., Ratliff T.L., Russell J.H. CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. J. Immunol. 1996, 157:2961-2968.
57. Williams C.B., Engle D.L., Kersh G.J., Michael White J., Allen P.M. A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex. J. Exp. Med. 1999, 189:1531-1544.
58. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 2000, 192:1637-1644.
59. Zhang B., Bowerman N.A., Salama J.K., Schmidt H., Spiotto M.T., Schietinger A., Yu P., Fu Y.X., Weichselbaum R.R., Rowley D.A., et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 2007, 204:49-55.
60. Zhang B., Karrison T., Rowley D.A., Schreiber H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 2008, 118:1398-1404.